BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib.

Byrgazov, Konstantin

BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib. [electronic resource] - Haematologica 01 2018 - e10-e12 p. digital

Publication Type: Letter; Research Support, Non-U.S. Gov't

1592-8721

10.3324/haematol.2017.176347 doi


Alleles
Amino Acid Substitution
Antineoplastic Agents--pharmacology
Dose-Response Relationship, Drug
Drug Resistance, Neoplasm--genetics
Fusion Proteins, bcr-abl--genetics
Gene Expression
Humans
Imidazoles--pharmacology
Mutation
Pharmacogenomic Testing
Pharmacogenomic Variants
Protein Kinase Inhibitors--pharmacology
Pyridazines--pharmacology